Combined use with memantine has not been systematically evaluated. Both are NMDA antagonists and such use should be approached with caution.
Source: NLP:memantine hydrochloride oral
Brand names: Memantine Hydrochloride
Route: Oral
Contraindications
4 CONTRAINDICATIONS Memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. ( 4 ) Memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of memantine in pregnant women. Adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. These doses are higher than those used in humans at the maximum recommended daily dose of memantine [see Data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats during the period of organogenesis resulted in decreased skeletal ossification in fetuses at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg) is 3 times the maximum recommended human daily dose (MRHD) of memantine (20 mg) on a body surface area (mg/m 2 ) basis. Oral administration of memantine to rabbits (0, 3, 10, or 30 mg/kg/day) during the period of organogenesis resulted in no adverse developmental effects. The highest dose tested is approximately 30 times the MRHD of memantine on a mg/m 2 basis. In rats, memantine (0, 2, 6, or 18 mg/kg/day) was administered orally prior to and throughout mating and, in females, through the period of organogenesis or continuing throughout lactation to weaning. Decreased skeletal ossification in fetuses and decreased body weight in pups were observed at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg/day) is 3 times the MRHD of memantine on a mg/m 2 basis. Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats from late gestation throughout lactation to weaning, resulted in decreased pup weights at the highest dose tested. Th
5 interactions on record
Combined use with memantine has not been systematically evaluated. Both are NMDA antagonists and such use should be approached with caution.
Source: NLP:memantine hydrochloride oral
Combined use with memantine has not been systematically evaluated. Both are NMDA antagonists and such use should be approached with caution.
Source: NLP:memantine hydrochloride oral
Combined use with memantine has not been systematically evaluated. Both are NMDA antagonists and such use should be approached with caution.
Source: NLP:memantine hydrochloride oral
Carbonic anhydrase inhibitors alter urine pH towards alkaline conditions, which may reduce memantine clearance by about 80% and lead to drug accumulation and increased adverse effects.
Source: NLP:memantine hydrochloride oral
Sodium bicarbonate alters urine pH towards alkaline conditions, which may reduce memantine clearance by about 80% and lead to drug accumulation and increased adverse effects.
Source: NLP:memantine hydrochloride oral